Biltema Foundation supports cancer research

Biltema Foundation supports cancer research

Biltema Foundation continues its commitment to fight cancer by supporting the development of the latest technology in cancer treatment.

We continue our support for the development of FLASH therapy, a technique that makes it possible to treat cancer forms that would otherwise require surgery. FLASH therapy uses high doses of radiation to eliminate tumors without leaving any trace. No chemotherapy is needed, making it a gentler treatment method for patients.

The research is being conducted at the Lausanne University Hospital in collaboration with CERN (CERN is the world's largest particle physics laboratory located in Geneva) as the developer of the technology. Biltema Foundation is the main funder of the research on FLASH therapy in Lausanne. Since its start in 2016, Biltema Foundation has donated 425 million SEK. The project is managed both operationally and scientifically in collaboration with the ISREC Foundation.

"Biltema Foundation is proud to support research on FLASH therapy, which we believe will have a significant positive impact on patients. We are committed to finding solutions to improve the lives of those affected by cancer", says Adelina Voci, spokesperson for the Biltema Foundation.

A machine is currently being built that will revolutionize the way we look at cancer treatment. The project is schedule from September 2021 to 2025, including clinical trials and treatment of patients, technical design, construction of infrastructure, collaboration with industrial partners, construction and assembly of the prototype, and approval by the Swiss health authorities.

Biltema Foundation has previously supported the development of new treatment technology for skin cancer and is now looking forward to continuing its fight against cancer by supporting FLASH therapy.

Read more about FLASH therapy:

https://www.lausanneuniversityhospital.com/tackling-cancer-treatment-resistance-with-flash

 

Detailed timeline:

  • Start of clinical trials and treatment of first patients: September 2021
  • Technical design: January 2023
  • Construction of infrastructure: February 2023 to February 2024
  • Design with industrial partner: March 2023
  • Construction and assembly of prototype: 2024-2025
  • Testing and approval by Swiss health authorities: 2025